Endologix Company Profile (NASDAQ:ELGX)

About Endologix (NASDAQ:ELGX)

Endologix logoEndologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Devices & Implants
  • Sub-Industry: Health Care Supplies
  • Symbol: NASDAQ:ELGX
  • CUSIP: 29266S10
  • Web: www.endologix.com
  • Market Cap: $440.6 million
  • Outstanding Shares: 82,975,000
Average Prices:
  • 50 Day Moving Avg: $4.88
  • 200 Day Moving Avg: $6.12
  • 52 Week Range: $4.20 - $14.41
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.30
  • P/E Growth: -0.22
Sales & Book Value:
  • Annual Revenue: $193.17 million
  • Price / Sales: 2.28
  • Book Value: $1.14 per share
  • Price / Book: 4.66
  • EBIDTA: ($61,290,000.00)
  • Net Margins: -66.43%
  • Return on Equity: -48.92%
  • Return on Assets: -16.16%
  • Debt-to-Equity Ratio: 1.89%
  • Current Ratio: 2.80%
  • Quick Ratio: 1.74%
  • Average Volume: 1.36 million shs.
  • Beta: 0.65
  • Short Ratio: 16.46
Frequently Asked Questions for Endologix (NASDAQ:ELGX)

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) announced its quarterly earnings data on Thursday, May, 4th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.06. The business earned $42.60 million during the quarter, compared to analyst estimates of $41.15 million. Endologix had a negative return on equity of 48.92% and a negative net margin of 66.43%. Endologix's revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.25) earnings per share. View Endologix's Earnings History.

Where is Endologix's stock going? Where will Endologix's stock price be in 2017?

11 brokers have issued twelve-month price objectives for Endologix's shares. Their predictions range from $5.00 to $15.00. On average, they anticipate Endologix's share price to reach $7.55 in the next twelve months. View Analyst Ratings for Endologix.

What are analysts saying about Endologix stock?

Here are some recent quotes from research analysts about Endologix stock:

  • 1. According to Zacks Investment Research, "Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. " (7/24/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: May 18, 2017, 12:09 ET Date and time of production: May 18, 2017, 12:09 ET Target Price / Valuation Methodology: CRH Medical Corporation – CRHM Price target of $8 is based on 15x 2018E adj-EBITDA to common, a premium to its peer group of outsourced health care services providers. We believe that is justified given the faster growth and higher margin profile of CRHM relative to peers. Risks to achieving Target Price / Valuation: CRH Medical Corporation – CRHM Negative reimbursement rate cuts or other regulatory changes could adversely impact market for anesthesia services. Should the level of acquisitions not meet our expectations, or should acquisitions not integrate and contribute to profitability as expected, CRH financial results could be below our expectations. Margin compression is possible as M&A activity ramps up." (5/18/2017)

Who are some of Endologix's key competitors?

Who are Endologix's key executives?

Endologix's management team includes the folowing people:

  • Daniel T. Lemaitre, Chairman of the Board
  • Robert D. Mitchell, President
  • John D. McDermott, Chief Executive Officer, Director
  • Vaseem Mahboob, Chief Financial Officer, Corporate Secretary
  • Michael V. Chobotov Ph.D., Chief Technology Officer
  • David M. Jennings, Vice President - Human Resources
  • Amanda L. DePalma, Vice President - Global Marketing
  • Meredith O. Huetter, Vice President - Global Medical Affairs
  • Michael P. Maszy, Vice President - Manufacturing
  • Laura Nagel, Vice President - Global Quality

Who owns Endologix stock?

Endologix's stock is owned by a number of of retail and institutional investors. Top institutional investors include GW&K Investment Management LLC (0.19%) and NN Investment Partners Holdings N.V. (0.08%). Company insiders that own Endologix stock include Amanda L Depalma, Charles Steele Love, Dan Lemaitre, Gregory D Waller, Guido J Neels, James Edward Machek, John D Mcdermott, Jose A Lima, Joseph A Dejohn, Michael V Chobotov, Robert D Mitchell, Thomas F Zenty III, Todd Abraham and Vaseem Mahboob. View Institutional Ownership Trends for Endologix.

Who sold Endologix stock? Who is selling Endologix stock?

Endologix's stock was sold by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC. Company insiders that have sold Endologix stock in the last year include Jose A Lima and Michael V Chobotov. View Insider Buying and Selling for Endologix.

Who bought Endologix stock? Who is buying Endologix stock?

Endologix's stock was bought by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V.. Company insiders that have bought Endologix stock in the last two years include Dan Lemaitre, Guido J Neels, John D Mcdermott, Robert D Mitchell, Thomas F Zenty III, Todd Abraham and Vaseem Mahboob. View Insider Buying and Selling for Endologix.

How do I buy Endologix stock?

Shares of Endologix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endologix's stock price today?

One share of Endologix stock can currently be purchased for approximately $5.31.

MarketBeat Community Rating for Endologix (NASDAQ ELGX)
Community Ranking:  2.5 out of 5 (  )
Outperform Votes:  260 (Vote Outperform)
Underperform Votes:  255 (Vote Underperform)
Total Votes:  515
MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Endologix (NASDAQ:ELGX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 9 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.18)
Consensus Price Target: $7.55 (42.18% upside)

Analysts' Ratings History for Endologix (NASDAQ:ELGX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/5/2017Stifel NicolausReiterated RatingBuy$5.00 -> $5.50MediumView Rating Details
5/18/2017Oppenheimer Holdings, Inc.DowngradeOutperform -> Market Perform$6.00MediumView Rating Details
5/18/2017Royal Bank Of CanadaReiterated RatingHoldMediumView Rating Details
5/18/2017BMO Capital MarketsReiterated RatingHold$5.00HighView Rating Details
5/18/2017Canaccord GenuityReiterated RatingHold$5.00HighView Rating Details
5/18/2017StephensDowngradeOverweight -> Equal Weight$6.00HighView Rating Details
5/18/2017BTIG ResearchDowngradeBuy -> Neutral$7.00HighView Rating Details
12/7/2016Leerink SwannReiterated RatingMarket Perform$11.00 -> $8.00N/AView Rating Details
12/4/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$14.00 -> $10.00N/AView Rating Details
11/16/2016GuggenheimDowngradeBuy -> NeutralN/AView Rating Details
8/3/2016Piper Jaffray CompaniesReiterated RatingOverweight$15.00N/AView Rating Details
2/22/2016Credit Suisse GroupLower Price TargetOutperform$16.00 -> $10.00N/AView Rating Details
(Data available from 7/25/2015 forward)


Earnings History for Endologix (NASDAQ:ELGX)
Earnings by Quarter for Endologix (NASDAQ:ELGX)
Earnings History by Quarter for Endologix (NASDAQ ELGX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.24)($0.18)$41.15 million$42.60 millionViewListenView Earnings Details
2/22/2017Q4 2016($0.19)($0.22)$48.69 million$47.46 millionViewListenView Earnings Details
11/1/2016Q316($0.15)($0.11)$51.83 million$52.12 millionViewN/AView Earnings Details
8/2/2016Q2($0.20)($0.20)$46.30 million$51.00 millionViewListenView Earnings Details
5/9/2016Q1($0.24)($0.25)$38.78 million$42.40 millionViewN/AView Earnings Details
2/22/2016Q4($0.16)($0.08)$39.97 million$39.20 millionViewListenView Earnings Details
10/26/2015Q315($0.14)($0.13)$38.12 million$38.20 millionViewListenView Earnings Details
8/3/2015Q215($0.13)($0.18)$39.47 million$39.50 millionViewN/AView Earnings Details
4/29/2015Q115($0.13)($0.14)$37.94 million$36.70 millionViewN/AView Earnings Details
2/25/2015Q414($0.10)($0.11)$38.10 million$38.80 millionViewN/AView Earnings Details
10/30/2014Q314($0.13)($0.13)$37.00 million$37.20 millionViewListenView Earnings Details
7/30/2014Q214($0.08)($0.06)$36.50 million$38.30 millionViewListenView Earnings Details
4/30/2014Q114($0.08)($0.08)$32.24 million$33.30 millionViewListenView Earnings Details
2/27/2014Q413($0.05)($0.05)$35.80 million$35.25 millionViewListenView Earnings Details
10/30/2013Q313($0.05)$0.01$32.47 million$33.30 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.06)($0.03)$33.94 million$34.00 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)($0.15)$29.26 million$29.80 millionViewN/AView Earnings Details
2/27/2013Q4 2012($0.03)($0.09)$29.03 million$29.22 millionViewN/AView Earnings Details
10/25/2012($0.04)($0.03)ViewN/AView Earnings Details
7/26/2012($0.04)($0.09)ViewN/AView Earnings Details
4/26/2012($0.06)($0.07)ViewN/AView Earnings Details
2/22/2012($0.05)($0.06)ViewN/AView Earnings Details
10/27/2011($0.05)($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Endologix (NASDAQ:ELGX)
2017 EPS Consensus Estimate: ($0.65)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.22)($0.22)
Q2 20172($0.18)($0.16)($0.17)
Q3 20172($0.16)($0.11)($0.14)
Q4 20172($0.13)($0.12)($0.13)
(Data provided by Zacks Investment Research)


Dividend History for Endologix (NASDAQ:ELGX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Endologix (NASDAQ:ELGX)
Insider Ownership Percentage: 4.10%
Insider Trades by Quarter for Endologix (NASDAQ:ELGX)
Institutional Ownership by Quarter for Endologix (NASDAQ:ELGX)
Insider Trades by Quarter for Endologix (NASDAQ:ELGX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2017Dan LemaitreDirectorBuy22,522$4.43$99,772.46View SEC Filing  
5/19/2017Guido J NeelsDirectorBuy20,000$4.32$86,400.00View SEC Filing  
5/19/2017Robert D MitchellPresidentBuy2,200$4.32$9,504.00View SEC Filing  
12/14/2016John D McdermottCEOBuy10,000$6.67$66,700.00View SEC Filing  
12/14/2016Thomas F Zenty IIIDirectorBuy3,000$6.51$19,530.00View SEC Filing  
12/13/2016Vaseem MahboobCFOBuy20,000$6.25$125,000.00View SEC Filing  
11/18/2016Guido J NeelsDirectorBuy13,000$7.69$99,970.00View SEC Filing  
8/19/2016Jose A LimaVPSell4,710$11.68$55,012.80View SEC Filing  
8/5/2016Michael V ChobotovInsiderSell14,000$12.40$173,600.00View SEC Filing  
6/3/2016Gregory D WallerDirectorSell7,800$12.86$100,308.00View SEC Filing  
6/1/2016Amanda L DepalmaVPSell689$12.55$8,646.95View SEC Filing  
6/1/2016John D McdermottCEOSell6,116$12.55$76,755.80View SEC Filing  
6/1/2016Joseph A DejohnInsiderSell957$12.55$12,010.35View SEC Filing  
6/1/2016Robert D MitchellPresidentSell2,294$12.55$28,789.70View SEC Filing  
5/26/2016James Edward MachekVPSell6,500$12.76$82,940.00View SEC Filing  
1/26/2016Charles Steele LoveVPSell4,280$7.72$33,041.60View SEC Filing  
11/3/2015Guido J NeelsDirectorBuy11,000$9.32$102,520.00View SEC Filing  
11/3/2015Todd AbrahamVPBuy2,500$8.85$22,125.00View SEC Filing  
11/2/2015John D McdermottCEOBuy20,000$8.90$178,000.00View SEC Filing  
9/3/2015Jose A LimaVPSell1,923$12.60$24,229.80View SEC Filing  
5/26/2015Thomas WilderDirectorSell3,790$16.08$60,943.20View SEC Filing  
5/20/2015Jose A LimaVPSell1,872$16.75$31,356.00View SEC Filing  
4/6/2015Robert D MitchellPresidentSell45,000$17.33$779,850.00View SEC Filing  
12/12/2014Charles Steele LoveVPSell10,000$13.95$139,500.00View SEC Filing  
11/18/2014Charles Steele LoveVPBuy2,000$11.70$23,400.00View SEC Filing  
11/4/2014Guido J NeelsDirectorBuy10,000$11.21$112,100.00View SEC Filing  
11/4/2014John D McdermottCEOBuy25,000$11.25$281,250.00View SEC Filing  
8/4/2014Thomas WilderDirectorSell3,500$13.68$47,880.00View SEC Filing  
6/12/2014Robert D MitchellPresidentSell18,271$14.23$259,996.33View SEC Filing  
6/10/2014Robert D MitchellPresidentSell8,516$14.20$120,927.20View SEC Filing  
8/14/2013Stefan SchreckVPSell25,000$16.18$404,500.00View SEC Filing  
8/13/2013Stefan SchreckVPSell29,000$15.88$460,520.00View SEC Filing  
8/5/2013Gary SorsherVPSell12,483$15.98$199,478.34View SEC Filing  
8/5/2013John McdermottCEOSell165,000$16.00$2,640,000.00View SEC Filing  
8/2/2013Todd AbrahamVPSell9,994$15.90$158,904.60View SEC Filing  
8/1/2013John D McdermottCEOSell15,000$15.83$237,450.00View SEC Filing  
6/3/2013Thomas WilderDirectorSell22,500$13.25$298,125.00View SEC Filing  
5/28/2013Leonard M GreensteinVPSell1,253$14.01$17,554.53View SEC Filing  
12/28/2012Robert John KristCFOSell37,530$14.06$527,671.80View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Endologix (NASDAQ:ELGX)
Latest Headlines for Endologix (NASDAQ:ELGX)
americanbankingnews.com logoSt Jude Medical (STJ) versus Endologix (NASDAQ:ELGX) Head-To-Head Survey
www.americanbankingnews.com - July 25 at 12:28 AM
americanbankingnews.com logoEndologix, Inc. (ELGX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - July 24 at 10:56 PM
businesswire.com logoRobbins Arroyo LLP Is Investigating the Officers and Directors of Endologix, Inc. (ELGX) on Behalf of Shareholders - Business Wire (press release)
www.businesswire.com - July 21 at 8:07 PM
americanbankingnews.com logoReviewing Endologix (ELGX) & Glaukos Corporation (GKOS)
www.americanbankingnews.com - July 19 at 12:24 PM
businesswire.com logoEndologix, Inc. to Announce Second Quarter 2017 Financial Results on August 2, 2017 - Business Wire (press release)
www.businesswire.com - July 14 at 5:38 AM
finance.yahoo.com logoEndologix, Inc. to Announce Second Quarter 2017 Financial Results on August 2, 2017
finance.yahoo.com - July 12 at 6:51 PM
businesswire.com logoEndologix, Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference - Business Wire (press release)
www.businesswire.com - July 10 at 11:11 PM
finance.yahoo.com logoEndologix, Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - July 10 at 6:08 PM
americanbankingnews.com logo Brokerages Expect Endologix, Inc. (NASDAQ:ELGX) Will Announce Quarterly Sales of $47.67 Million
www.americanbankingnews.com - July 7 at 11:16 AM
americanbankingnews.com logoZacks: Analysts Anticipate Endologix, Inc. (NASDAQ:ELGX) Will Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - July 5 at 10:18 PM
americanbankingnews.com logoEndologix (NASDAQ:ELGX) & Second Sight Medical Products (EYES) Head to Head Contrast
www.americanbankingnews.com - July 4 at 8:25 AM
prnewswire.com logoLifshitz & Miller LLP Announces Investigation of Aaron's, Inc., Axiom ... - PR Newswire (press release)
www.prnewswire.com - July 4 at 4:10 AM
americanbankingnews.com logoEndologix, Inc. (NASDAQ:ELGX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 3 at 10:16 AM
americanbankingnews.com logoReviewing Endologix (ELGX) & Stryker Corporation (SYK)
www.americanbankingnews.com - June 25 at 8:06 PM
prnewswire.com logoMedical Supplies Stocks on Investors' Radar -- Endologix, Microbot ... - PR Newswire (press release)
www.prnewswire.com - June 21 at 6:28 PM
americanbankingnews.com logoUnilife Corp (UNIS) and Endologix (ELGX) Critical Survey
www.americanbankingnews.com - June 21 at 6:15 PM
prnewswire.com logoENDOLOGIX ALERT: J&W Investigates Endologix, Inc.; Long Term Investors Encouraged to Contact the Firm - PR Newswire (press release)
www.prnewswire.com - June 14 at 6:00 PM
finance.yahoo.com logoENDOLOGIX ALERT: J&W Investigates Endologix, Inc.; Long Term Investors Encouraged to Contact the Firm
finance.yahoo.com - June 13 at 12:03 PM
finance.yahoo.com logoRobbins Arroyo LLP: Endologix, Inc. (ELGX) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - June 12 at 5:50 PM
americanbankingnews.com logo$47.67 Million in Sales Expected for Endologix, Inc. (ELGX) This Quarter
www.americanbankingnews.com - June 11 at 7:46 AM
americanbankingnews.com logo-$0.19 Earnings Per Share Expected for Endologix, Inc. (ELGX) This Quarter
www.americanbankingnews.com - June 9 at 10:28 PM
finance.yahoo.com logoEndologix, Inc. (ELGX)
finance.yahoo.com - June 8 at 5:56 PM
americanbankingnews.com logoEndologix, Inc. (ELGX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - June 6 at 9:50 AM
americanbankingnews.com logoStifel Nicolaus Reaffirms Buy Rating for Endologix, Inc. (ELGX)
www.americanbankingnews.com - June 5 at 10:00 PM
streetinsider.com logoEndologix (ELGX) Reports Positive Two-Year Clinical Data from the Nellix EVAS FORWARD IDE Trial - StreetInsider.com
www.streetinsider.com - June 5 at 5:01 PM
finance.yahoo.com logoEndologix Presents Positive Two-Year Clinical Data from the Nellix® EVAS FORWARD IDE Trial
finance.yahoo.com - June 3 at 4:50 PM
streetinsider.com logoEndologix (ELGX) Announces Positive Clinical Data from Ovation LUCY Study
www.streetinsider.com - June 1 at 10:39 PM
benzinga.com logoEndologix, Inc. (NASDAQ:ELGX) - Endologix Reports Positive ... - Benzinga
www.benzinga.com - June 1 at 5:38 PM
feeds.benzinga.com logoEndologix Reports Positive Clinical Data from the Ovation LUCY Study with 1.3% Major Adverse Event
feeds.benzinga.com - June 1 at 5:28 AM
rttnews.com logoEndologix Reports Positive Clinical Data From Ovation LUCY Study
www.rttnews.com - June 1 at 2:55 AM
nasdaq.com logoFDA Greenlights Novo Nordisk's Rebinyn, TEVA's HALO Shines, LUCY Walks The Talk
www.nasdaq.com - June 1 at 2:55 AM
finance.yahoo.com logoEndologix Reports Positive Clinical Data from the Ovation LUCY Study
finance.yahoo.com - May 31 at 9:54 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Endologix, Inc. – ELGX
finance.yahoo.com - May 26 at 5:33 PM
finance.yahoo.com logoETFs with exposure to Endologix, Inc. : May 26, 2017
finance.yahoo.com - May 26 at 5:33 PM
americanbankingnews.com logoFY2018 EPS Estimates for Endologix, Inc. Decreased by Leerink Swann (ELGX)
www.americanbankingnews.com - May 24 at 1:08 PM
americanbankingnews.com logoInsider Buying: Endologix, Inc. (ELGX) Director Acquires 22,522 Shares of Stock
www.americanbankingnews.com - May 23 at 4:32 PM
americanbankingnews.com logoInsider Buying: Endologix, Inc. (ELGX) Director Purchases 20,000 Shares of Stock
www.americanbankingnews.com - May 23 at 1:27 PM
americanbankingnews.com logoEndologix, Inc. to Post FY2018 Earnings of ($0.59) Per Share, Oppenheimer Holdings Forecasts (ELGX)
www.americanbankingnews.com - May 22 at 8:50 AM
seekingalpha.com logoEndologix Needs Confirmatory Study For Nellix EVAS System - Seeking Alpha
seekingalpha.com - May 20 at 9:53 PM
rttnews.com logoEndologix Inc. (ELGX) Plunged To A New Low After FDA Meeting
www.rttnews.com - May 19 at 8:05 AM
finance.yahoo.com logoWhy Endologix, Inc. Is Getting Crushed Today
finance.yahoo.com - May 19 at 8:05 AM
americanbankingnews.com logoEndologix, Inc. (ELGX) Lowered to "Market Perform" at Oppenheimer Holdings Inc.
www.americanbankingnews.com - May 18 at 10:56 PM
americanbankingnews.com logoRoyal Bank of Canada Reaffirms Hold Rating for Endologix, Inc. (ELGX)
www.americanbankingnews.com - May 18 at 9:40 PM
americanbankingnews.com logoEndologix, Inc. (ELGX) Earns Hold Rating from BMO Capital Markets
www.americanbankingnews.com - May 18 at 5:20 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Walmart, L Brands, Endologix, Cisco, Stein Mart - Nasdaq
www.nasdaq.com - May 18 at 5:14 PM
americanbankingnews.com logoEndologix, Inc. (ELGX) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - May 18 at 1:32 PM
americanbankingnews.com logoEndologix, Inc. (ELGX) Stock Rating Lowered by Stifel Nicolaus
www.americanbankingnews.com - May 18 at 1:00 PM
feeds.benzinga.com logoAnalyst On Endologix: No Sense In Downgrading Now
feeds.benzinga.com - May 18 at 11:43 AM
rttnews.com logoEndologix Inc. (ELGX) Has Dropped To A New Low For The Year
www.rttnews.com - May 18 at 10:28 AM
americanbankingnews.com logoEndologix, Inc. (ELGX) Stock Rating Lowered by BTIG Research
www.americanbankingnews.com - May 18 at 9:54 AM



Endologix (ELGX) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by MarketBeat.com Staff